July 11, 2016

Dear BioSig Shareholder:

The current year has been a period of significant growth and achievement for us here at BioSig Technologies, Inc. (OTCQB: BSGM). We have established strong partnerships in the market as we have gathered valuable data on the effectiveness of our novel PURE EP™ System.

 

Our proprietary technology, PURE EP™ System is aimed at the $4 billion cardiac electrophysiology (EP) marketplace, which is growing at 12.1% CAGR and is the fastest growing segment of cardiology. EP is the science of diagnosing and treating abnormal electrical activities of the heart (arrhythmias). An arrhythmia (abnormal heart rhythm) is a change in the heart’s beating pattern. There are many different types with different causes and effects. An abnormal heart rhythm is when your heart beats too fast, too slowly or irregularly. According to the Center for Disease Control, as many as 6.1 million people in the United States have Atrial Fibrillation, just one form of arrhythmia. With the aging of the U.S. population, this number is expected to increase. Our goal is to provide physicians with more accurate, relevant real-time data during diagnostic EP studies and catheter ablation treatments for mainly the complex arrhythmias, Ventricular Tachycardia (VT) and Atrial Fibrillation (AF). We believe that our technology should prove valuable to the marketplace through improved quality of care for these wide-reaching conditions.

With our recent achievements in preclinical trials, the Company has begun to more actively communicate our message to members of the medical and investment community. In March, at the 13th Annual International Dead Sea Symposium (IDSS) in Israel, our collaborative effort with Mayo Clinic was presented entitled, “Enhanced Electrophysiology Recording Improves Signal Acquisition & Differentiation.” In May, Management attended Heart Rhythm

Society’s 37th Annual Scientific Sessions in San Francisco; and, we plan on presenting at the 8th Annual International Conference of  the IEEE Engineering in Medicine and Biology Society in Orlando from August 17–20. These scientific/medical conferences bring together key experts, leading doctors and scientists, as well as other health professionals in our space, and are ideal platforms for us to share our PURE EP™ System and our dedication to improving the space and patient care.

In addition to connecting with leading healthcare experts, the company also has begun to selectively communicate with the investment community. We presented at the LD Micro Invitational, the Roth Growth Conference, the Drexel Hamilton Investor Forum and others. These conferences have given us the opportunity to directly interact with investors, analysts and journalists regarding the strategic growth drivers for BioSig. The initial feedback has been positive, as the investment community begins to better understand the problem at hand and our potential to successfully address it. BioSig will continue to support the exposure of this technology as the audience develops and we achieve certain milestones.

Ventricular tachycardia prevalence continues to increase as more and more people are surviving heart attacks. Scar tissue in the lower chambers of the heart often results from a heart attack – this scarring can lead to rapid abnormal rhythms that interfere with the heart pumping blood, causing fainting and even sudden cardiac arrest. Approximately 450,000 sudden cardiac arrests occur in the US each year.

As the awareness of complex arrhythmias increases, patients invariably seek options for treatment. Drug therapies and implantable devices have often proved ineffective or resulted in debilitating side effects. Catheter ablation, the form of treatment that the PURE EP™ system is designed to support, has become an increasingly more popular and effective treatment. Ablation procedures for AF and VT are oftentimes empirical and 2-8 hours in length; and, many patients need repeated procedures to treat their disorder. The PURE EP™ System is designed to retain true cardiac signal data and display vital information that is currently undetectable with today’s technology. Supplying physicians with these signals in a usable format provided by PURE EP™ may lead to more effective procedures and better patient outcomes.

There is an increasing demand in the field for new technologies to treat these complex arrhythmias. Additionally, there is a drastic shortage of innovators who are able to address the problem. This imbalance of supply/demand creates a unique value proposition for our shareholders. Additionally, the medical technology industry continues to show indicators of

bullish activity. There have been significant valuation premiums placed on similar companies, due to the significant merger and acquisition activity in the sector. There have been several major acquisitions made in the past 18 months of innovators by strategic medical device companies: Abbott (NYSE: ABT) bought Topera for $350 million, Medtronic (NYSE: MDT) bought CardioInsight for $272 million and AtriCure (NASDAQ: ATRC) bought nContact for $149 million. In February of this year, Medical device company Stryker Corp. (NYSE: SYK) announced that it would acquire defibrillator maker Physio-Control International for $1.28 billion in cash. Most notably, Abbott also announced a $25 billion definitive agreement with St. Jude Medical, Inc. to enter the atrial fibrillation, structural heart, heart failure and neuromodulation markets. These buyouts are proof that elite technologies operating in this booming industry can demand premium valuations.

systems. In December 2014, we began our research program with Dr. Samuel Asirvatham at the Mayo Clinic in Rochester, Minnesota. Based upon the success of our preclinical trials at Mayo Clinic throughout 2015, we announced in January a new Advanced Research Initiative, which triples our investment to fully characterize and develop novel features for generation II of our PURE EP™ System. The first of these nine studies has been successfully completed with the next planned for later this month. We also completed our first study at Mount Sinai Hospital in New York with Drs. Vivek Reddy and Jacob Koruth.

The objective of our preclinical studies is to demonstrate the clinical potential of PURE EP™, and yield results not obtainable with present recording systems. Once the studies have been completed, we plan to publish the results at industry conferences and peer-reviewed journals in 2016.

In February, BioSig initiated a development deal for its PURE EP™ System with Minnetronix, an award-winning medical technology development and manufacturing firm. Minnetronix is widely considered to be a market leader in design, development, manufacturing, commercialization and service of medical electronic and electromechanical products. This deal is important as we move through testing towards commercialization of our technology and into production. Management is currently developing a Quality Management System (QMS) and beginning to formulate our 510(k) submission to the Food and Drug Administration. The  FDA 510(k) premarket  notification submission  is  based on a comparison of your device to another medical device that has already been cleared by the FDA (called the Predicate Device). The submission is scheduled for early 2017. Finally, we have also identified a notified body to help us obtain a CE Mark, required for commercial release in Europe.

On May 3, 2016, we announced the completion of a $4.5 million private placement. BioSig issued 3,003,016 common shares at a price of $1.50 per share and a half warrant with a three-year expiration at a cash exercise price of $1.95. Board members and insiders purchased $630,000 of the $4.5M, or approximately 12.5% of the deal – and this is not the first time we have seen insider participation in our financing activities. The continued investment from insiders represents the strong confidence we have in our technology and our ability to commercialize our platform. The proceeds of this deal will be used to drive our clinical, technology and commercialization efforts forward. In addition to providing us with a strong foundation of working capital, the deal provided us with access to a strategic network of committed investors with a proven track record of assisting emerging-growth medtech companies to reach critical mass. Having secured a significant capital infusion, it is a priority of BioSig to see its shares up-list to a national exchange, NASDAQ or the New York Stock Exchange. This “up-listing” will provide us access to a broader range of investors while enhancing our status throughout the med tech industry. We will strive to complete this move during the current calendar year.

2017. Additionally, the Company expects to file at least two additional patents within the year. Management believes that significant potential exists within the intellectual property aspects of the medical device arena and will continue to drive value for us in the long term. With an influx of capital, an enhanced IP portfolio and a widespread foundation of investors, we are strongly positioned to establish ourselves as a market innovator within this rapidly growing industry.

On behalf of our management team and our Board of Directors, we want to thank you again for your continued support. We are looking forward to a busy and exciting year as we work to leverage the opportunities ahead in order to establish BioSig Technologies as a market leader within the medical technology industry.

Sincerely,

/s/ Gregory D. Cash

Mr. Gregory D. Cash

President and Chief Executive Officer BioSig Technologies, Inc. (BSGM)  www.biosigtech.com